Possible therapeutic uses of salvia triloba and piper nigrum in alzheimer's disease-induced rats

Journal of Medicinal Food

Volumn 16, Issue 5, 2013, Pages 437-446

  Ahmed, Hanaa H ^a   Salem, Ahmed M ^b   Sabry, Gilane M ^b   Husein, Ahmed A ^c   Kotob, Soheir E ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Ain Shams University   (Egypt)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Alzheimer's disease; neuroinflammation; Piper nigrum; rats; Salvia triloba

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BLACK PEPPER EXTRACT; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; RIVASTIGMINE; SALVIA TRILOBA EXTRACT; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLACK PEPPER; CONTROLLED STUDY; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SALVIA; SALVIA TRILOBA; TREATMENT DURATION;

ALZHEIMER DISEASE; ANIMALS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; HUMANS; MALE; NF-KAPPA B; PIPER NIGRUM; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SALVIA;

EID: 84877873056     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0165     Document Type: Article

References (99)

1. Nie K, Yu JC, Fu Y, Cheng HY, Chen FY, Qu Y, Han JX: Age-related decrease in constructive activation of Akt/PKB in SAMP10 hippocampus. Biochem Biophys Res Commun 2009; 378:103-107.
2. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR: Butterfield DA: Preclinical Alzheimer's disease: brain oxidative stress, amyloid-beta peptide and pro-teomics. Neurobiol Dis 2010;39:221-228.
3. Sehgal N: Resolution of neuroinflammation by cytochrome P4504F: implication in Alzheimer's disease. Alzheimer's Demen 2009;5:483
4. Terry AV, Buccafusco JJ: Cholinergic hypothesis of age and Alzeheimer's disease related cognitive deficits: recent challenges and their implications in novel drug development. J Pharmacol Exp Ther 2003;306:821-827.
5. Walton JR: An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. J Inorg Biochem 2007;101:1275-1284.
6. Wisniewski HM, Sturman JA, Shek JW: Aluminium chloride induced neurofibrillary changes in the developing rabbit: a chronic animal model. Ann Neurol 1980;8:479-490.
7. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C: Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009;12:826-828.
8. Sastre M, Klockgether T, Heneka MT: Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006;24:167-176.
9. Reale M, Iarlori C, Feliciani C, Gambi D: Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 2008;14:147-159.
10. Dos Santos-Neto LL, de Vilhena Toledo MA, Medeiros-Souza P, de Souza GA: The use of herbal medicine in Alzheimer's disease: a systematic review. Evid Based Complement Alternat Med 2006;3:441-445.
11. Baricevic D, Bartol T: The biological/pharmacological activity of the Salvia genus. In: Sage, the genus Salvia (Kintzios SE, ed.). Harwood Academic Publishers, Amsterdam, 2000, pp. 143-184.
12. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Me-nichini F: Cytotoxic activity of essential oils from Labiatae and Lauraceae families against in vitro human tumor models. Anticancer Res 2007;27:3293-3299.
13. Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, Zupancic A: Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. J Eth-nopharmacol 2001;75:125-132.
14. Fellah S, Diouf PN, Petrissans M, Perrin D, Romdhane M, Ab-derrabba M: Chemical composition and antioxidant properties of Salvia officinalis L. oil from two culture sites in Tunisia. J Essent Oil Res 2006;18:553-556.
15. Lee VMY, Carden MJ, Schlaepfer WW, Trojanowski JQ: Monoclonal antibodies distinguish several differentially phos-phorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci 1987;7:3474-3488.
16. Durairajan SK, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang J, Klein WL, Li M: Salvianolic acid B inhibits Ab fibril formation and disaggregates preformed fibrils and protects against Ab-induced cytotoxicity. Neurochem Int 2008; 52:741-750.
17. Quijano M, Callejas R, Miranda D: Areas of endemism and distribution patterns for neotropical Piper species (Piperaceae). J Biogeog 2006;33:1266-1278.
18. Portet B, Fabre N, Roumy V, Gornitzka H, Bourdy G, Chevalley S, Sauvain M, Valentin A, Moulis C: Activity-guided isolation of antiplasmodial dihydrochalcones and avanones from Piper hostmannianum var. Berbicense. Phytochem 2007;68:1312-1320.
19. Flores N, Cabrera G, Jiménez IA, Piñero J, Giménez A, Bourdy G, Cortés-Selva F, Bazzocchi IL: Leishmanicidal constituents from the leaves of Piper rusbyi. Planta Med 2007;73:206-211.
20. Rukachaisirikul T, Siriwattanakit P, Sukcharoenphol K, Wong-vein C, Ruttanaweang P, Wongwattnavuch P, Suksamrarn A: Chemical constituents and bioactivity of Piper sarmentosum. J Ethnopharmacol 2004;93:173-176.
21. Rali T, Wossa SW, Leach DN, Waterman PG: Volatile constituents of Piper aduncum and Piper gibbilimbum C.DC (Piper-aceae) from Papua New Guinea. Molecules 2007;12:389-394.
22. Moreira DL, Guimaraes EF, Kaplan MAC: A chromene from Piper aduncum. Phytochemistry 1998;48:1075-1077.
23. Lago JHG, Ramos CS, Casanova DCC, Moradin AA, Bergamo DCB, Furlan M, Cavahleiro AJ, Bolzani VS, Young MCM, Guimaraes EF, Kato MJ: Benzoic acid derivatives from Piper species and their fungitoxic activity against Cladosporium cla-dosporioides and C. sphaerospermum. J Nat Prod 2004;67: 1783-1788.
24. Gupta SK, Bansal P, Bhardwaj RK, Velpandian T: Comparative antinociceptive, anti-inflammatory and toxicity profile of nime-sulide vs. nimesulide and piperine combination. Pharmacol Res 2000;41:657-662.
25. D'Hooge R, Pei YQ, Raes A, Lebrun P, Van Bogaert PP, De Deyn PP: Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. Arzneimittelforschung 1996;46:557-560.
26. Lee SA, Hong SS, Han XH, Hwang JS, Oh GJ, Lee KS, Lee MK, Hwang BY, Ro JS. Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem Pharm Bull 2005;53:832-835.
27. Selvendiran K, Singh JP, Krishnan KB, Sakthisekaran D: Cytoprotective effect of piperine against benzo[a]pyrene induced lung cancer with reference to lipid peroxidation and antioxidant system in Swiss albino mice. Fitoterapia 2003;74: 109-115.
28. Orhan I, Aslan M: Appraisal of scopolamine-induced anti-amnesic effect in mice and in vitro antiacetylcholinesterase and antioxidant activities of some traditionally used Lamiaceae plants. J Ethnopharmacol 2009;122:327-332.
29. Rasheed M, Afshan F, Tariq RM, Siddiqui BS, Gulzar T, Mah-mood A, Begum S, Khan B: Phytochemical studies on the seed extract of Piper nigrum Linn. Natl Prod Res 2005;19:703-712.
30. Krasovskii GN, Vasukovich LY, Chariev OG: Experimental study of biological effects of leads and aluminum following oral administration. Environ Health Perspect 1979;30:47-51.
31. 2+-, ATPase activities, antioxidant status, and learning performance of aged rats. Neuropsychiatr Dis Treat 2008;4: 687-699.
32. 2+-ATPase activities induced by the in vitro galactosaemia. Pharmacol Res 2004;49:475-479.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol 1951;193:265-275.
34. Karthikeyan K, Bai BR, Devaraj SN: Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocar-dial injury in rats. Int J Cardiol 2007;115:326-333.
35. Den Blawen DH, Poppe WA, Trischier W: Cholinesterase (EC 3.1.1.8) with butyryl thiocholine-iodide as substrate: reference depending on age and sex with special reference to hormonal effect and pregnancy. J Clin Chem Biochem 1983;21:381-386.
36. Oswald C, Smits SH, Hoing M, Sohn-Bosser L, Dupont L, Le Rudulier D, Schmitt L, Bremer E: Crystal structures of choline/acetylcholine substrate-binding protein chox from Sinorhizobium meliloti in the liganded and unliganded-closed states. J Biol Chem 2008;283:32848-32859.
37. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N: Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-468.
38. Adams J: Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-619.
39. Ikawa T, Ikeda M, Yamaguchi A, Tsai WC, Tamura N, Seta N, Trucksess M, Raybourne RB, Yu DT: Expression of arthritis-causing HLAB27 on HeLa cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J Clin Invest 1998;101:263-272.
40. Armitage P, Berry G: Statistical Methods in Medical Research, 2nd ed. Blackwell Scientific Publications, Oxford, 1987, pp. 186-213.
41. Kumar A, Dogra S, Prakash A: Protective effect of curcumin (Curcuma longa) against aluminum toxicity: possible behavioral and biochemical alterations in rats. Behav Brain Res 2009;205: 384-390.
42. Zhang J, Yang JQ, He BC, Zhou QX, Yu HR, Tang Y, Liu BZ: Berberine and total base from rhizoma Coptis chinensis attenuate brain injury in an aluminum-induced rat model of neurodegen-erative disease. Saud Med J 2009;30:760-766.
43. Zubenko GS, Hanin I: Cholinergic and noradrenergic toxicity of intraventricular aluminum chloride in the rat hippocampus. Brain Res 1989;498:381-384.
44. Bielarczyk H, Tomaszewicz M, Szutowicz A: Effects of aluminum on acetyl-CoA and aetylcholine metabolism in nerve terminals. J Neurochem 1998;70:1175-1118.
45. Szutowicz A: Aluminum, NO and nerve growth factor neurotox-icity in cholinergic neurons. J Neurosci Res 2001;66:1009-1018.
46. Alleva K, Rankin J, Santucci D: Neurobehavioural alteration in rodents following developmental exposure to aluminum. Toxicol Ind Health 1998;14:209-221.
47. Liang YQ, Tang XC: Comparative effects of huperzine A, do-nepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 2004;361: 56-59.
48. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3: 211-225.
49. Figiel G, Sadowsky CA: Systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008;24:157-166.
50. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C: Rivastigmine is a potent inhibitor of acetyl-and butyr-ylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005;1060:144-152.
51. Giacobini E, Cuadra G: Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Alzheimer Disease: Therapeutic Strategies (Giacobini E, Becker R, eds.). Birkhäuser, Boston, MA, 1994, pp. 155-171.
52. Táyebati SK, Di Tullio MA, Amenta F: Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcho-line transporter and choline acetyltransferase in rat brain. Clin Exp Hypertens 2004;26:363-373.
53. Perry NSL, Houghton PJ, Jenner P, Keith A, Perry EK: Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine 2002;9:48-51.
54. Loizzo MR, Tundis R, Menichini F, Menichini F: Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. Curr Med Chem 2008;15:1209-1228.
55. Perry NS, Houghton PJ, Sampson J, Theobald AE Hart S, Lis-Balchin M, Hoult JR, Evans P, Jenner P, Milligan S, Perry EK: In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol 2001; 53:1347-1356.
56. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry EK: Syn-ergistic and antagonistic interactions of anticholinsterase terpe-noids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 2003;75:661-668.
57. Ji HF, Zhang HY: Multipotent natural agents to combat Alzheimer's disease: functional spectrum and structural features. Acta Pharmacol Sin 2008;29:143-151.
58. Ingkaninan K, Temkitthawon P, Chuenchom K, Yuyaem T, Thongnoi W: Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J Ethnopharmacol 2003;89:261-264.
59. Chonpathompikunlert P, Wattanathorn J, Muchimapura S: Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. Food Chem Toxicol 2010;48:798-802.
60. Mukherjee PK, Kumar V, Mal M, Houghton PJ: Acetylcholinesterase inhibitors from plants. Phytomedicine 2007;14:289-300.
61. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C: Blood inflammatory markers and risk of dementia: the conselice study of brain aging. Neurobiol Aging 2007;28:1810-1820.
62. Teunissen CE, van Boxtel MP, Bosma H: Inflammation markers in relation to cognition in a healthy aging population. J Neu-roimmunol 2003;134:142-150.
63. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Witteman JC, Breteler M: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004;61:668-672.
64. Yasojima K, Schwab C, McGeer EG, McGeer PL: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000;887:80-89.
65. McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging 2001;22:799-809.
66. Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, Weinstock M, Brenner T: Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivas-tigmine. J Neuroimmunol 2008;203:12-22.
67. Nizri E, Irony-Tur-Sinai M, Lavon I, Meshulam H, Amitai G, Brenner T: IBU-octyl-cytisine, a novel bifunctional molecule eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity. Int Im-munopharmacol 2007;7:1129-1139.
68. Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, Aarden LA, Yap SH: The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988;155:112-117.
69. Pollak Y, Gilboa A, Ben-Menachem O, Ben-Hur T, Soreq H, Yirmiya R: Acetylcholinesterase inhibitors reduce brain and blood interleukin-1b production. Ann Neurol 2005; 57:741-745.
70. Xu G, Zhao W, Zhou Z, Zhang R, Zhu W, Liu X: Danshen extracts decrease blood c reactive protein and prevent ischemic stroke recurrence: a controlled pilot study. Phytother Res 2009;23:1721-1725.
71. Zhang Q, Chang Z, Yang J, Wang Q: Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza. Phytother Res 2008;22:1040-1045.
72. Peng Q, Xiang M, Long S, Chen L: Effect of Salvia miltiorrhiza injection on CRP and adhesion molecule in the type II diabetic nephropathy patient blood. J Jishou Univ Nat Sci Ed 2010;2010-01, DOI: cnki:sun:jsdn.0.2010-01-029.
73. Amran AA, Zakaria Z, Das S, Al-Mekhlafi HM, Nordin NMM: Changes in the vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and C-reactive protein following administration of aqueous extract of Piper sarmentosum on experimental rabbits fed with cholesterol diet. Lipids Health Dis 2011;10:2-8.
74. Alan LM: Antioxidant flavonoids structure, function and clinical using. Altern Med Rev 1996;1:103-111.
75. Seong CC, Hyo SK, Tae SJ, Song HB, Young BP: Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2001;38:947-955.
76. Yoshiyama Y, Arai K, Hattori T: Enhanced expression of I-kappaB with neurofibrillary pathology in Alzheimer's disease. Neuro Rep 2001;12:2641-2645.
77. Huang Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX: NF-jB precursor, p105, and NF-jB inhibitor, IjBc, are both elevated in Alzheimer disease brain. Neurosci Lett 2005;373:115-118.
78. Campbell A, Becaria A, Sharman K, Bondy SC: Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res 2004;75:565-572.
79. Lukiw WJ, Percy ME, Kruck TP: Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 2005;99: 1895-1898.
80. Pizzi M, Spano P: Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol 2006;545:22-28.
81. Wang J, Slunt H, Gonzales V, Fromholt D, Coonfield M, Co-peland NG, Jenkins NA, Borchelt DR: Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum Mol Genet 2003; 12:2753-2764
82. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, Ulloa L: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10:1216-1221.
83. Tabet N: Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing. Age Ageing 2006; 35:336-338.
84. Niu XL, Ichimori K, Yang X, Hirota Y, Hoshiai K, Li M, Na-kazawa H: Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radic Res 2000;33:305-312.
85. Lee P, Hur J, Lee J, Kim J, Jeong J, Kang I, Kim SY, Kim H: 15, 16-Dihydrotanshinone I suppresses the activation of BV-2 cell, a murine microglia cell line, by lipopolysaccharide. Neurochem Int 2006;48:60-66.
86. Chen X, Zhou C, Guoc J, Sunb K, Zhaob N, Yang J, Sun Y, Hibid T, Liu Z, Hanb J: Effects of dihydroxylphenyl lactic acid on inflammatory responses in spinal cord injury. Brain Res 2011;13:160-168.
87. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO: Tanshinone IIA inhibits LPS-induced NF-jB activation in RAW 264.7 cells: Possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 2006;542:1-7.
88. Hwang YP, Yun HJ, Kim HG, Han EH, Choi JH, Chung YC, Jeong HG: Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCa/ERK1/2-dependent matrix metalloproteinase-9 expression. Toxicol Lett 2011;203:9-19.
89. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C: Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008;56:4855-4873.
90. Karpus WJ: Chemokines and central nervous system disorders. J Neurovirol 2001;7:493-500.
91. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD: Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007;13:432-438.
92. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C: The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010;224:93-100.
93. Thompson WL, Van Eldik LJ: Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-7 through NFkappaB and MAPK dependent pathways in rat astrocytes. Brain Res 2009;1287:47-57.
94. Kim SY, Park E, Park JA, Choi BS, Kim S, Jeong G, Kim CS, Kim DK, Kim SJ, Chun HS: The plant phenolic diterpene car-nosol suppresses sodium nitroprusside-induced toxicity in C6 glial cells. J Agric Food Chem 2010;58:1543-1550.
95. Pocivavsek A, Burns MP, Rebeck GW: Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 2009;57:444-453.
96. Waetzig V, Herdegen T: Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci Lett 2004;361:64-67
97. Ren ZH, Tong YH, Xu W, Ma J, Chen Y: Tanshinone IIA attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 2010;17: 212-218.
98. Zhang YJ, Xu YF, Liu YH, Liu YH, Yin J, Li HL, Wang Q, Wang JZ: Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J 2006;20:1431-1442.
99. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R: Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 2007;80:926-931.